News

Erlotinib Fails as Maintenance Therapy for Ovarian Cancer

Publish date: July 20, 2012

 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Vergote disclosed no relevant conflicts of interest. Dr. Seiden disclosed no relevant conflicts of interest.

Pages

Recommended Reading

ASCO: Stop Underdosing Obese Cancer Patients
MDedge Hematology and Oncology
Evidence Suggests Pregnancies Can Survive Maternal Cancer Treatment
MDedge Hematology and Oncology
Study Fine-Tunes Link Between Endometriosis, Ovarian Cancer
MDedge Hematology and Oncology
New Dermoscopic Insights Gleaned for Mucosal Lesions
MDedge Hematology and Oncology
Fertility Preservation No Longer Experimental for Cancer Patients
MDedge Hematology and Oncology
Adding Bevacizumab Doubles PFS in Hard-to-Treat Ovarian Cancer
MDedge Hematology and Oncology
Effective Second-Line Agents Identified for Anti-NMDA Receptor Encephalitis
MDedge Hematology and Oncology
FDA Warns of QT Prolongation with Ondansetron Dose
MDedge Hematology and Oncology
FDA Approves REMS for Long-Acting Opioids
MDedge Hematology and Oncology
Olaparib Defers Progression of Serous Ovarian Cancer - Again
MDedge Hematology and Oncology